Abiomed's heart pump gets EU nod
(Reuters) - Abiomed Inc said European health regulators approved the use of its heart pump in cardiac surgery.
The Danvers, Massachusetts-based company said the device, called Impella cVAD, is expected to be commercially available in Europe by this summer.
The device is intended for use in cardiac surgery for supporting the weakened heart's left ventricle, which is responsible for pumping oxygen-rich blood from the lungs throughout the body.
Impella cVAD is still not approved in the United States.
Abiomed shares closed at $20.90 on Wednesday on the Nasdaq.
(Reporting by Anand Basu in Bangalore; Editing by Viraj Nair)
- Tweet this
- Share this
- Digg this
- Missing Air Algerie plane from Burkina Faso has crashed - Algerian official
- Alabama man sues, claiming penis amputated instead of circumcised
- Taiwan launches inquiry into plane crash that killed 48
- Wipro sees strong sales growth, eyes Europe deals
- Honda's Mobilio car looks to repeat Indonesia success in India
Nigeria could cut the number of polio cases to zero next year and be declared free of the disease in 2018 even though a national eradication campaign has had to contend with an insurgency in the north, Bill Gates told Reuters. Full Article